Opexa Therapeutics Inc  

(Public, NASDAQ:OPXA)   Watch this stock  
Find more results for OPXA
+0.01 (0.33%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.78 - 3.02
52 week 2.33 - 8.64
Open 3.02
Vol / Avg. 0.00/112,496.00
Mkt cap 20.43M
P/E     -
Div/yield     -
EPS -3.58
Shares 6.67M
Beta 1.54
Inst. own 12%
Nov 4, 2015
Q3 2015 Opexa Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Opexa Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Aug 12, 2015
Q2 2015 Opexa Therapeutics Inc Earnings Call
Aug 12, 2015
Q2 2015 Opexa Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -481.47% -1183.45%
Operating margin -483.17% -1184.67%
EBITD margin - -1154.19%
Return on average assets -90.73% -79.13%
Return on average equity -164.99% -107.45%
Employees 39 -
CDP Score - -


2635 Technology Forest Blvd
THE WOODLANDS, TX 77381-3905
United States - Map
+1-281-2729331 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company's T-cell technology. It is engaged in the field of Precision Immunotherapy. The Company's product candidates include Tcelna and OPX-212. Tcelna and OPX-212 are not approved by the United States Food and Drug Administration (FDA) or other global regulatory agencies for marketing. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. In addition to the Company's ongoing clinical development of Tcelna, the Company is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Officers and directors

Neil K. Warma President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Karthik Radhakrishnan CFA Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Donna R. Rill Chief Development Officer
Age: 61
Bio & Compensation  - Reuters
Timothy C. Barabe Director
Age: 62
Bio & Compensation  - Reuters
Hans-Peter Hartung M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael S. Richman Independent Director
Age: 54
Bio & Compensation  - Reuters
Scott B. Seaman CPA Independent Director
Age: 59
Bio & Compensation  - Reuters